These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 35455458)

  • 1. Transcriptomic Analysis of Fumarate Compounds Identifies Unique Effects of Isosorbide Di-(Methyl Fumarate) on NRF2, NF-kappaB and IRF1 Pathway Genes.
    Swindell WR; Bojanowski K; Chaudhuri RK
    Pharmaceuticals (Basel); 2022 Apr; 15(4):. PubMed ID: 35455458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel fumarate, isosorbide di-(methyl fumarate) (IDMF), replicates astrocyte transcriptome responses to dimethyl fumarate (DMF) but specifically down-regulates genes linked to a reactive phenotype.
    Swindell WR; Bojanowski K; Chaudhuri RK
    Biochem Biophys Res Commun; 2020 Nov; 532(3):475-481. PubMed ID: 32892947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Sensitization-Free Dimethyl Fumarate Prodrug, Isosorbide Di-(Methyl Fumarate), Provides a Topical Treatment Candidate for Psoriasis.
    Bojanowski K; Ibeji CU; Singh P; Swindell WR; Chaudhuri RK
    JID Innov; 2021 Dec; 1(4):100040. PubMed ID: 34909741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.
    Naismith RT; Wundes A; Ziemssen T; Jasinska E; Freedman MS; Lembo AJ; Selmaj K; Bidollari I; Chen H; Hanna J; Leigh-Pemberton R; Lopez-Bresnahan M; Lyons J; Miller C; Rezendes D; Wolinsky JS;
    CNS Drugs; 2020 Feb; 34(2):185-196. PubMed ID: 31953790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.
    Wray S; Then Bergh F; Wundes A; Arnold DL; Drulovic J; Jasinska E; Bowen JD; Negroski D; Naismith RT; Hunter SF; Gudesblatt M; Chen H; Lyons J; Shankar SL; Kapadia S; Mendoza JP; Singer BA
    Adv Ther; 2022 Apr; 39(4):1810-1831. PubMed ID: 35211872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews.
    Gudesblatt M; Roman C; Singer BA; Schmidt H; Thomas J; Shankar SL; Lyons J; Kapadia S
    Adv Ther; 2022 Jul; 39(7):3199-3213. PubMed ID: 35556227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
    Naismith RT; Wolinsky JS; Wundes A; LaGanke C; Arnold DL; Obradovic D; Freedman MS; Gudesblatt M; Ziemssen T; Kandinov B; Bidollari I; Lopez-Bresnahan M; Nangia N; Rezendes D; Yang L; Chen H; Liu S; Hanna J; Miller C; Leigh-Pemberton R
    Mult Scler; 2020 Nov; 26(13):1729-1739. PubMed ID: 31680631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies.
    Gopal S; Mikulskis A; Gold R; Fox RJ; Dawson KT; Amaravadi L
    Mult Scler; 2017 Dec; 23(14):1875-1883. PubMed ID: 28156185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study.
    Palte MJ; Wehr A; Tawa M; Perkin K; Leigh-Pemberton R; Hanna J; Miller C; Penner N
    Adv Ther; 2019 Nov; 36(11):3154-3165. PubMed ID: 31538304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice.
    Yao Y; Miao W; Liu Z; Han W; Shi K; Shen Y; Li H; Liu Q; Fu Y; Huang D; Shi FD
    Transl Stroke Res; 2016 Dec; 7(6):535-547. PubMed ID: 27614618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diroximel fumarate to treat multiple sclerosis.
    Wang Y; Bhargava P
    Drugs Today (Barc); 2020 Jul; 56(7):431-437. PubMed ID: 32648853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diroximel fumarate in the treatment of multiple sclerosis.
    Jonasson E; Sejbaek T
    Neurodegener Dis Manag; 2020 Oct; 10(5):267-276. PubMed ID: 32686599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dimethyl fumarate improves cognitive deficits in chronic cerebral hypoperfusion rats by alleviating inflammation, oxidative stress, and ferroptosis via NRF2/ARE/NF-κB signal pathway.
    Yan N; Xu Z; Qu C; Zhang J
    Int Immunopharmacol; 2021 Sep; 98():107844. PubMed ID: 34153667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The NRF2 transcriptional target, OSGIN1, contributes to monomethyl fumarate-mediated cytoprotection in human astrocytes.
    Brennan MS; Matos MF; Richter KE; Li B; Scannevin RH
    Sci Rep; 2017 Feb; 7():42054. PubMed ID: 28181536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DMF, but not other fumarates, inhibits NF-κB activity in vitro in an Nrf2-independent manner.
    Gillard GO; Collette B; Anderson J; Chao J; Scannevin RH; Huss DJ; Fontenot JD
    J Neuroimmunol; 2015 Jun; 283():74-85. PubMed ID: 26004161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental Investigations of Monomethyl and Dimethyl Fumarate in an Astrocyte-Microglia Co-Culture Model of Inflammation.
    Corvace F; Faustmann TJ; Heckers S; Faustmann PM; Ismail FS
    Pharmacology; 2023; 108(2):188-198. PubMed ID: 36724743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study.
    Wundes A; Wray S; Gold R; Singer BA; Jasinska E; Ziemssen T; de Seze J; Repovic P; Chen H; Hanna J; Messer J; Miller C; Naismith RT
    Ther Adv Neurol Disord; 2021; 14():1756286421993999. PubMed ID: 33796143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monomethyl fumarate treatment impairs maturation of human myeloid dendritic cells and their ability to activate T cells.
    Mazzola MA; Raheja R; Regev K; Beynon V; von Glehn F; Paul A; Pierre I; Kivisakk P; Weiner HL; Gandhi R
    Mult Scler; 2019 Jan; 25(1):63-71. PubMed ID: 29106333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a Population Pharmacokinetic Model for the Diroximel Fumarate Metabolites Monomethyl Fumarate and 2-Hydroxyethyl Succinimide Following Oral Administration of Diroximel Fumarate in Healthy Participants and Patients with Multiple Sclerosis.
    Kuchimanchi M; Bockbrader H; Dolphin N; Epling D; Quinlan L; Chapel S; Penner N
    Neurol Ther; 2022 Mar; 11(1):353-371. PubMed ID: 35041178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct Nrf2 Signaling Mechanisms of Fumaric Acid Esters and Their Role in Neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Experimental Parkinson's-Like Disease.
    Ahuja M; Ammal Kaidery N; Yang L; Calingasan N; Smirnova N; Gaisin A; Gaisina IN; Gazaryan I; Hushpulian DM; Kaddour-Djebbar I; Bollag WB; Morgan JC; Ratan RR; Starkov AA; Beal MF; Thomas B
    J Neurosci; 2016 Jun; 36(23):6332-51. PubMed ID: 27277809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.